CO2018002046A2 - New oral delayed dual dexlansoprazole oral composition - Google Patents

New oral delayed dual dexlansoprazole oral composition

Info

Publication number
CO2018002046A2
CO2018002046A2 CONC2018/0002046A CO2018002046A CO2018002046A2 CO 2018002046 A2 CO2018002046 A2 CO 2018002046A2 CO 2018002046 A CO2018002046 A CO 2018002046A CO 2018002046 A2 CO2018002046 A2 CO 2018002046A2
Authority
CO
Colombia
Prior art keywords
dexlansoprazole
oral
pharmaceutically acceptable
new
release layer
Prior art date
Application number
CONC2018/0002046A
Other languages
Spanish (es)
Inventor
Anwar Siraj Daud
Shamsuddin Jamaluddin
Original Assignee
Zim Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57884420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018002046(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zim Laboratories Ltd filed Critical Zim Laboratories Ltd
Publication of CO2018002046A2 publication Critical patent/CO2018002046A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona una composición farmacéutica oral de liberación retardada dual de Dexlansoprazol o sales farmacéuticamente aceptables o formas hidratadas del mismo. La composición farmacéutica de liberación retardada dual descrita puede incorporar dos formulaciones de liberación pulsátil (a) y (b), en donde la formulación (a) puede incluir: (i) una partícula de núcleo que comprende Dexlansoprazol o una sal farmacéuticamente aceptable o un hidrato del mismo, y (ii) una capa de liberación controlada dependiente del pH; y la formulación (b) puede incluir: (i) una partícula de núcleo que comprende Dexlansoprazol o una sal farmacéuticamente aceptable o un hidrato del mismo, (ii) una capa de liberación controlada independiente del pH, y (iii) una capa de liberación controlada dependiente del pH.The present disclosure provides a dual delayed-release oral pharmaceutical composition of Dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof. The described dual delayed release pharmaceutical composition may incorporate two pulsatile release formulations (a) and (b), wherein formulation (a) may include: (i) a core particle comprising Dexlansoprazole or a pharmaceutically acceptable salt or a hydrate thereof, and (ii) a pH dependent controlled release layer; and formulation (b) may include: (i) a core particle comprising Dexlansoprazole or a pharmaceutically acceptable salt or a hydrate thereof, (ii) a pH independent controlled release layer, and (iii) a release layer pH dependent controlled.

CONC2018/0002046A 2015-07-28 2018-02-26 New oral delayed dual dexlansoprazole oral composition CO2018002046A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2851MU2015 2015-07-28
PCT/IB2016/054467 WO2017017615A1 (en) 2015-07-28 2016-07-27 Novel dual delayed release oral composition of dexlansoprazole

Publications (1)

Publication Number Publication Date
CO2018002046A2 true CO2018002046A2 (en) 2018-02-28

Family

ID=57884420

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002046A CO2018002046A2 (en) 2015-07-28 2018-02-26 New oral delayed dual dexlansoprazole oral composition

Country Status (6)

Country Link
EP (1) EP3328364A4 (en)
BR (1) BR112018001539A2 (en)
CL (1) CL2018000220A1 (en)
CO (1) CO2018002046A2 (en)
PE (1) PE20181012A1 (en)
WO (1) WO2017017615A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111991367A (en) * 2020-09-21 2020-11-27 青岛吉达巴尔国际贸易有限公司 Esomeprazole magnesium pulse pellet capsule and preparation method thereof
KR102471545B1 (en) * 2020-11-20 2022-11-29 서울대학교 산학협력단 pH-dependent tablet-in-capsule combination formulation containing dexransoprazole as an active ingredient and method for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20120058194A1 (en) * 2010-08-27 2012-03-08 Navin Vaya Pharmaceutical formulations comprising substituted benzimidazole derivatives
WO2013111149A1 (en) * 2011-12-21 2013-08-01 Hetero Research Foundation Controlled release solid oral compositions of dexlansoprazole

Also Published As

Publication number Publication date
BR112018001539A2 (en) 2018-09-18
PE20181012A1 (en) 2018-06-26
EP3328364A1 (en) 2018-06-06
WO2017017615A1 (en) 2017-02-02
CL2018000220A1 (en) 2018-07-20
EP3328364A4 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
HRP20201812T1 (en) Hepatitis b core protein modulators
DOP2020000102A (en) HELPFUL COMPOUNDS TO INHIBIT CDK7
BR112018071585A2 (en) formulations of an lsd1 inhibitor
UY35933A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AZD9291
CL2017003320A1 (en) Pharmaceutical formulations containing tenofovir and emtricitabine
EA201792116A1 (en) JANUS KINASE INHIBITOR
AR122580A2 (en) DOSAGE FORM OF DOXYLAMINE AND PYRIDOXINE AND/OR THEIR METABOLITES OR SALTS
CO2018004776A2 (en) Therapeutic compositions for the treatment of human immunodeficiency virus
CO2018005842A2 (en) Pharmaceutical composition comprising a potent urat 1 inhibitor
AR128816A2 (en) PHARMACEUTICAL DOSAGE FORMS OF CYSTEAMINE PEARLS
AR096543A1 (en) QUINASE INHIBITORS PI3 d AND g DUAL SELECTIVES
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
UY36920A (en) FORMULATIONS OF AMINO ACIDS OF MODIFIED RELEASE ADMINISTERED BY ROUTE
CR20170314A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
CL2015003468A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
UY36124A (en) CARBOXAMIDE DERIVATIVES
CO2018002046A2 (en) New oral delayed dual dexlansoprazole oral composition
AR108233A1 (en) ORIC PHARMACEUTICAL COMPOSITIONS OF NICOTINAMIDE
CO2018014217A2 (en) Pharmaceutical compositions comprising safinamide
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
GT201400094A (en) IMMEDIATE RELEASE FORMULATION OF 4-METHYL-3 - [[4- (3-PIRIDINIL) -2-PYRIMIDINYL] AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- ( TRIFLUOROMETIL) -FENIL] -BENZAMIDA
CL2016000182A1 (en) Stable anti-tuberculosis pharmaceutical composition in a form of a coated tablet comprising isoniazid granules and rifapentin granules and their preparation process
AR103219A1 (en) COMPOSITE OF (1H-INDOL-3-IL) PROPAN-1-ONA, PHARMACEUTICAL COMPOSITION, COMBINATION AND MIXTURE THAT INCLUDE IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR124515A2 (en) 2-(1-(9H-PURIN-6-ILAMINO)PROPYL)-3-(3-FLUOROPHENYL)-4H-CHROMEN-4-ONE AND (S)-2-(1-(9H-PURIN-6-ILAMINO) )PROPYL)-3-(3-FLUOROPHENYL)-4H-CHROMEN-4-ONE, PHARMACEUTICAL COMPOSITION; RELATED METHODS, AND USE OF SUCH COMPOUNDS TO MANUFACTURE DRUGS